GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptamer Sciences Inc (XKRX:291650) » Definitions » EV-to-EBITDA

Aptamer Sciences (XKRX:291650) EV-to-EBITDA : -2.80 (As of May. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Aptamer Sciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aptamer Sciences's enterprise value is ₩32,670.5 Mil. Aptamer Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-11,655.0 Mil. Therefore, Aptamer Sciences's EV-to-EBITDA for today is -2.80.

The historical rank and industry rank for Aptamer Sciences's EV-to-EBITDA or its related term are showing as below:

XKRX:291650' s EV-to-EBITDA Range Over the Past 10 Years
Min: -59.21   Med: -24.15   Max: -2.5
Current: -2.8

During the past 7 years, the highest EV-to-EBITDA of Aptamer Sciences was -2.50. The lowest was -59.21. And the median was -24.15.

XKRX:291650's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Biotechnology industry
Industry Median: 9.55 vs XKRX:291650: -2.80

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Aptamer Sciences's stock price is ₩2810.00. Aptamer Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-801.000. Therefore, Aptamer Sciences's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Aptamer Sciences EV-to-EBITDA Historical Data

The historical data trend for Aptamer Sciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptamer Sciences EV-to-EBITDA Chart

Aptamer Sciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - -55.64 -35.78 -6.14 -3.96

Aptamer Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.14 -4.88 -4.79 -3.32 -3.96

Competitive Comparison of Aptamer Sciences's EV-to-EBITDA

For the Biotechnology subindustry, Aptamer Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptamer Sciences's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptamer Sciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aptamer Sciences's EV-to-EBITDA falls into.



Aptamer Sciences EV-to-EBITDA Calculation

Aptamer Sciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=32670.482/-11654.982
=-2.80

Aptamer Sciences's current Enterprise Value is ₩32,670.5 Mil.
Aptamer Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-11,655.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptamer Sciences  (XKRX:291650) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Aptamer Sciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2810.00/-801.000
=At Loss

Aptamer Sciences's share price for today is ₩2810.00.
Aptamer Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-801.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Aptamer Sciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aptamer Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptamer Sciences (XKRX:291650) Business Description

Traded in Other Exchanges
N/A
Address
172, Dolma-ro, Bundang-gu, 407 Ho, Healthcare Innovation Park, Gyeonggi-do, Seongnam-si, KOR, 13605
Aptamer Sciences Inc is a research and development based bio venture company. The company is focused on the Aptamer Technology Platform for the development of innovative therapeutic and diagnostic platforms. It develops and facilitates drug development and other diagnostic products.

Aptamer Sciences (XKRX:291650) Headlines

No Headlines